CA Participant, Immune System Therapeutics, announces positive response to blood cancer drug
Last Reviewed: 20/06/2011
Immune System Therapeutics (IST), recipient of an Early Stage Commercialisation grant, has announced that its new drug has shown a positive response in patients with multiple myeloma blood cancer. Read their media release.